Clinical trial
Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With…
NCT00052117 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00052117 |
|---|---|
| Title | Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral Regimens |
| Official title | A Phase 2, Randomized, Double-Blind, Dose-Ranging Study Of Capravirine (AG1549) In Combination With Kaletra (Trademark) and At Least 2 Nucleoside Reverse Transcriptase Inhibitors in Hiv-Infected Subjects Who Have Failed Antiretroviral Regimens Containing Protease Inhibitors, Nonnucleoside Reverse… |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | capravirine, Kaletra, 2 NRTIs |
| Enrollment | 300 |
| Start date | Jan 1, 2003 |
| Completion | May 1, 2005 |
| First posted | Jan 23, 2003 |
| Last update posted | Oct 10, 2007 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: